Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Locus Pharmaceuticals Inc.
DescriptionOral inhibitor of Tie-2, Ret, and p38 kinases
Molecular Target Tyrosine kinase receptor 2 (Tie2) ; Ret proto-oncogene (RET)
Mechanism of ActionMAP kinase (p38) inhibitor; RET inhibitor; Tyrosine kinase receptor 2 (Tie2) inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today